Full Text Journal Articles by
Author Alexander B Olawaiye

Advertisement

Find full text journal articles






FIGO staging for carcinoma of the vulva: 2021 revision.

Alexander B Olawaiye, Joseph Cotler, Mauricio A Cuello, Neerja Bhatla, Aikou Okamoto, Sarikapan Wilailak, Chittaranjan N Purandare, Gerhard Lindeque, Jonathan S Berek, Sean Kehoe,

To revise the FIGO staging for carcinoma of the vulva using a new approach that involves analyses of prospectively collected data. The FIGO Committee for Gynecologic Oncology reviewed the recent literature to gain an insight into the impact of the 2009 vulvar cancer staging revision. The Committee resolved to revise ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2021, 155(1):43-47]

Cited: 0 times

View full text PDF listing >>



Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy.

Michelle Heayn, Lauren B Skvarca, Li Zhu, Robert P Edwards, Alexander B Olawaiye, Francesmary Modugno, Esther Elishaev, Rohit Bhargava,

The chemotherapy response score (CRS) proposed by Bohm and colleagues in 2015 has been validated as a reproducible method for determining histopathologic response of tubo-ovarian carcinoma to neoadjuvant chemotherapy and stratifies tumor response into 3 groups: CRS1 is defined as minimal/no response, CRS2 as moderate response, and CRS3 as marked ... Read more >>

Int J Gynecol Pathol (International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists)
[2021, 40(3):278-285]

Cited: 1 time

View full text PDF listing >>



Advertisement

The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer.

Alexander B Olawaiye, Thomas P Baker, M Kay Washington, David G Mutch,

The American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging for all cancer sites has been periodically updated as a published manual for many years. The last update, the eighth edition AJCC Cancer Staging Manual went into use on January 1, 2018. The AJCC has since restructured and ... Read more >>

CA Cancer J Clin (CA: a cancer journal for clinicians)
[2021, 71(4):287-298]

Cited: 1 time

View full text PDF listing >>



Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B Olawaiye, Susan L Ellard, Johanne I Weberpals, Andrea E Wahner Hendrickson, Gini F Fleming, Stephen Welch, Neesha C Dhani, Tracy Stockley, Prisni Rath, Katherine Karakasis, Gemma N Jones, Suzanne Jenkins, Jaime Rodriguez-Canales, Michael Tracy, Qian Tan, Valerie Bowering, Smitha Udagani, Lisa Wang, Charles A Kunos, Eric Chen, Trevor J Pugh, Amit M Oza,

<h4>Background</h4>The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.<h4>Methods</h4>In this double-blind, randomised, placebo-controlled, phase 2 trial, women with measurable recurrent platinum-resistant or platinum-refractory high-grade serous ovarian ... Read more >>

Lancet (Lancet (London, England))
[2021, 397(10271):281-292]

Cited: 3 times

View full text PDF listing >>



Race-driven survival differential in women diagnosed with endometrial cancers in the USA.

Zachary D Horne, Solomiya R Teterichko, Scott M Glaser, Rodney E Wegner, Shaakir Hasan, Sarah M Crafton, Eirwen M Miller, Thomas C Krivak, Akila Viswanathan, Alexander B Olawaiye, Paniti Sukumvanich, Sushil Beriwal,

<h4>Objective</h4>African American women are increasingly being diagnosed with advanced and type II histology endometrial cancers. Outcomes have been observed to be worse in African American women, but whether or not race itself is a factor is unclear. We sought to evaluate the rates of diagnosis and outcomes on a stage-by-stage ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2020, 30(12):1893-1901]

Cited: 2 times

View full text PDF listing >>



Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, Richard T Penson, Susan T Schumer, L Austin Doyle, Elizabeth K Lee, Elise C Kohn, Linda R Duska, Marta A Crispens, Alexander B Olawaiye, Ira S Winer, Lisa M Barroilhet, Siqing Fu, Michael T McHale, Russell J Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne S Quinn, Brittany Bowes, Alan D D'Andrea, Geoffrey I Shapiro, Ursula A Matulonis,

<h4>Background</h4>High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2020, 21(7):957-968]

Cited: 17 times

View full text PDF listing >>



Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

Phuong L Mai, Austin Miller, Mitchell H Gail, Steven Skates, Karen Lu, Mark E Sherman, Olga B Ioffe, Gustavo Rodriguez, David E Cohn, John Boggess, Thomas Rutherford, Noah D Kauff, Janet S Rader, Kelly-Anne Phillips, Paul A DiSilvestro, Alexander B Olawaiye, Mildred R Ridgway, Mark H Greene, Marion Piedmonte, Joan L Walker,

<h4>Background</h4>Risk-reducing salpingo-oophorectomy (RRSO) has been associated with approximately 50% breast cancer risk reduction among women with a pathogenic variant in <i>BRCA1</i> or <i>BRCA2</i> (<i>BRCA1/2</i>), a finding that has recently been questioned.<h4>Methods</h4>We estimated incidence rates of breast cancer and all cancers combined during 5 years of follow-up among participants selecting RRSO ... Read more >>

JNCI Cancer Spectr (JNCI cancer spectrum)
[2020, 4(1):pkz075]

Cited: 2 times

View full text PDF listing >>



No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.

Ronald J Buckanovich, Gordon Rustin, Shitanshu Uppal, Alexander B Olawaiye, Joseph L Kelley, Jessica L Berger, Charles N Landen,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(29):2707-2708]

Cited: 0 times

View full text PDF listing >>



Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.

Alexander B Olawaiye, Charles A Leath,

Uterine clear cell cancer (UCCC) is a rare but aggressive disease. Due to its rarity, large, prospective studies focused on UCCC are exceedingly difficult therefore available data are generally from small, retrospective studies. There is also pertinent information from subsection analysis of larger studies that include UCCC and other histotypes. ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2019, 155(2):365-373]

Cited: 1 time

View full text PDF listing >>



GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

Rebecca A Brooks, David S Tritchler, Kathleen M Darcy, Heather A Lankes, Ritu Salani, Paul Sperduto, Saketh Guntupalli, Paul DiSilvestro, Joshua Kesterson, Alexander B Olawaiye, Katherine Moxley, Steven Waggoner, Alessandro Santin, Janet S Rader, Nora T Kizer, Premal H Thaker, Matthew A Powell, David G Mutch, Michael J Birrer, Paul J Goodfellow,

<h4>Objectives</h4>The ability to stratify a patient's risk of metastasis and survival permits more refined care. A proof of principle study was undertaken to investigate the relationship between single nucleotide polymorphisms (SNPs) in literature based candidate cancer genes and the risk of nodal metastasis and clinical outcome in endometrioid endometrial cancer ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2019, 153(2):335-342]

Cited: 1 time

View full text PDF listing >>



Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.

Uzoma K Iheagwara, John A Vargo, Katherine S Chen, Danielle R Burton, Sarah E Taylor, Jessica L Berger, Michelle M Boisen, John T Comerci, Brian C Orr, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, Madeleine B Courtney-Brooks, Sushil Beriwal,

<h4>Purpose</h4>The role of neoadjuvant chemoradiation therapy in locally advanced type II endometrial cancer is controversial. We thus aimed to present our experience with the hypothesis that neoadjuvant chemoradiation therapy is associated with similarly high rates of downstaging and locoregional control for type II endometrial cancer and type I endometrial cancer.<h4>Methods ... Read more >>

Pract Radiat Oncol (Practical radiation oncology)
[2019, 9(4):248-256]

Cited: 1 time

View full text PDF listing >>



Revised FIGO staging for carcinoma of the cervix uteri.

Neerja Bhatla, Jonathan S Berek, Mauricio Cuello Fredes, Lynette A Denny, Seija Grenman, Kanishka Karunaratne, Sean T Kehoe, Ikuo Konishi, Alexander B Olawaiye, Jaime Prat, Rengaswamy Sankaranarayanan, James Brierley, David Mutch, Denis Querleu, David Cibula, Michael Quinn, Hennie Botha, Lax Sigurd, Laurel Rice, Hee-Sug Ryu, Hextan Ngan, Johanna Mäenpää, Andri Andrijono, Gatot Purwoto, Amita Maheshwari, Uttam D Bafna, Marie Plante, Jayashree Natarajan,

<h4>Objective</h4>To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.<h4>Methods</h4>Review of literature and consensus view of the FIGO Gynecologic Oncology Committee and related societies and organizations.<h4>Results</h4>In stage I, revision of the definition of microinvasion ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2019, 145(1):129-135]

Cited: 88 times

View full text PDF listing >>



Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Alexander B Olawaiye, James J Java, Thomas C Krivak, Michael Friedlander, David G Mutch, Gretchen Glaser, Melissa Geller, David M O'Malley, Robert M Wenham, Roger B Lee, Diane C Bodurka, Thomas J Herzog, Michael A Bookman,

Gynecol Oncol (Gynecologic oncology)
[2019, 152(1):220]

Cited: 0 times

View full text PDF listing >>



Single-Institution Experience in 3D MRI-Based Brachytherapy for Cervical Cancer for 239 Women: Can Dose Overcome Poor Response?

Zachary D Horne, Pooja Karukonda, Ronny Kalash, Robert P Edwards, Joseph L Kelley, John T Comerci, Alexander B Olawaiye, Madelaine Courtney-Brooks, Michelle M Bochmeier, Jessica L Berger, Sarah E Taylor, Paniti Sukumvanich, Sushil Beriwal,

<h4>Purpose</h4>Recent Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology guidelines recommend that the dose to 90% (D90) of the high-risk clinical target volume (HRCTV) in cervical cancer be at least 85 Gy, with higher doses for poor response to radiation therapy.<h4>Methods and materials</h4>A retrospective review of brachytherapy delivered at a ... Read more >>

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2019, 104(1):157-164]

Cited: 1 time

View full text PDF listing >>



Uterine sarcomas.

Nomonde Mbatani, Alexander B Olawaiye, Jaime Prat,

Uterine sarcomas account for approximately 3%-7% of all uterine cancers. Since carcinosarcomas are currently classified as metaplastic carcinomas, leiomyosarcomas remain the most common subtype. Exclusion of several histologic variants of leiomyoma, as well as atypical smooth muscle tumors (so-called "smooth muscle tumors of uncertain malignant potential"), has highlighted that the ... Read more >>

Int J Gynaecol Obstet (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics)
[2018, 143 Suppl 2:51-58]

Cited: 14 times

View full text PDF listing >>



Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Rebecca C Arend, Michael D Toboni, Allison M Montgomery, Robert A Burger, Alexander B Olawaiye, Bradley J Monk, Thomas J Herzog,

The treatment of metastatic and recurrent uterine leoimyosarcoma (uLMS) has evolved rapidly in the past several years. Leoimyosarcoma is extremely aggressive and responds poorly to traditional chemotherapeutics. Recent regulatory approval of novel treatment options has significantly expanded the therapeutic armamentarium, and the addition of these therapies has challenged clinicians to ... Read more >>

Oncologist (The oncologist)
[2018, 23(12):1533-1545]

Cited: 5 times

View full text PDF listing >>



Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Alexander B Olawaiye, James J Java, Thomas C Krivak, Michael Friedlander, David G Mutch, Gretchen Glaser, Melissa Geller, David M O'Malley, Robert M Wenham, Roger B Lee, Diane C Bodurka, Thomas J Herzog, Michael A Bookman,

PURPOSE:To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin and paclitaxel. METHODS:Women with stages III and IV EOC and PPC treated on the ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2018, 151(1):18-23]

Cited: 1 time

View full text PDF listing >>



Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.

Brian J Gebhardt, John A Vargo, Hayeon Kim, Christopher J Houser, Scott M Glaser, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, John T Comerci, Madeleine Courtney-Brooks, Sushil Beriwal,

<h4>Purpose</h4>Brachytherapy is integral to vaginal cancer treatment and is typically delivered using an intracavitary single-channel vaginal cylinder (SCVC) or an interstitial brachytherapy (ISBT) applicator. Multi-channel vaginal cylinder (MCVC) applicators allow for improved organ-at-risk (OAR) sparing compared to SCVC while maintaining target coverage. We present clinical outcomes of patients treated with ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2018, 150(2):293-299]

Cited: 7 times

View full text PDF listing >>



The Prognostic Significance of p16 Status in Patients With Vulvar Cancer Treated With Vulvectomy and Adjuvant Radiation.

Michael J Dohopolski, Zachary D Horne, Dinesh Pradhan, Rohit Bhargava, Robert P Edwards, Joseph L Kelley, John T Comerci, Alexander B Olawaiye, Madeleine Courtney-Brooks, Jessica L Berger, Paniti Sukumvanich, Sushil Beriwal,

<h4>Purpose</h4>Vulvar squamous cell carcinoma (VSCC) is a relatively rare malignancy. Human papillomavirus has been implicated as a causative factor for a subset of these patients. The purpose of this study was to evaluate whether p16-positivity (a human papillomavirus surrogate) predicts for better response rates in women who undergo surgery followed ... Read more >>

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2019, 103(1):152-160]

Cited: 1 time

View full text PDF listing >>



Chemo First, Then Radiation, and Perhaps Surgery.

Alexander B Olawaiye,

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2018, 100(2):290-291]

Cited: 0 times

View full text PDF listing >>



Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?

Michael J Dohopolski, Zachary D Horne, Brian J Gebhardt, Scott M Glaser, Robert P Edwards, Joseph L Kelley, John T Comerci, Alexander B Olawaiye, Madeleine Courtney-Brooks, Jessica L Berger, Paniti Sukumvanich, Sushil Beriwal,

PURPOSE:Vaginal brachytherapy (VBT) alone has been shown to be a viable adjuvant treatment strategy for most patients with Stage I endometrioid endometrial cancer. We sought to examine our institutional data following practice pattern changes resulting from the publications of GOG-99 and PORTEC-2. METHODS AND MATERIALS:We retrospectively analyzed women who underwent ... Read more >>

Brachytherapy (Brachytherapy)
[2018, 17(3):564-570]

Cited: 1 time

View full text PDF listing >>



Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.

Grzegorz T Gurda, Kate M Serdy, Svetlana A Yatsenko, Aleksandar Rajkovic, Natalie J Carter, Rafay Ahmed, Alexander B Olawaiye, Rohit Bhargava, Esther Elishaev,

We report the first case of distinct, synchronous serous carcinomas of the adnexa arising in a patient with a family history of breast and ovarian cancer and a germline loss of function mutation in BRCA1. Illustrating an exceedingly rare phenomenon of synchronous high-grade carcinomas with distinct histomorphologic, immunohistochemical and cytogenetic ... Read more >>

Int J Gynecol Pathol (International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists)
[2018, 37(2):117-122]

Cited: 2 times

View full text PDF listing >>



Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual.

Alexander B Olawaiye, David G Mutch,

Gynecol Oncol (Gynecologic oncology)
[2018, 150(1):7-8]

Cited: 2 times

View full text PDF listing >>



Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.

Michelle M Boisen, J Austin Vargo, Sushi Beriwal, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, Marilyn Huang, Madeleine Courtney-Brooks, John T Comerci,

<h4>Objectives</h4>Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2017, 27(6):1149-1154]

Cited: 2 times

View full text PDF listing >>



A Comparison of Thermal Plasma Energy Versus Argon Beam Coagulator-Induced Intestinal Injury After Vaporization in a Porcine Model.

Edward J Tanner, Erica Dun, Yukio Sonoda, Alexander B Olawaiye, Dennis S Chi,

<h4>Objectives</h4>Complete cytoreduction of ovarian cancer often requires excision or ablation of bowel serosa implants. Both argon beam coagulator (ABC) and thermal plasma energy (TPE) (PlasmaJet; PlasmaSurgical, Roswell, Ga) have been used to ablate bowel serosa implants. Our objective was to identify comparable power settings as well as determine the rate ... Read more >>

Int J Gynecol Cancer (International journal of gynecological cancer : official journal of the International Gynecological Cancer Society)
[2017, 27(1):177-182]

Cited: 1 time

View full text PDF listing >>



Advertisement


Disclaimer

1.0269 s